Vaccine effectiveness against COVID-19 hospitalisation in
adults (≥ 20 years) during Alpha- and Delta-dominant
circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks,
Europe, 2021

J 2023

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021

ANGELA, MC Rose; Nathalie NICOLAY; Virginia Sandonis MARTIN; Clara MAZAGATOS; Goranka PETROVIC et al.

Základní údaje

Originální název

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021

Autoři

ANGELA, MC Rose; Nathalie NICOLAY; Virginia Sandonis MARTIN; Clara MAZAGATOS; Goranka PETROVIC; F Annabel NIESSEN; Ausenda MACHADO; Odile LAUNAY; Sarah DENAYER; Lucie SEYLER; Joaquin BARUCH; Cristina BURGUI; Isabela I LOGHIN; Lisa DOMEGAN; Roberta VAIKUTYTE; Petr HUSA; George PANAGIOTAKOPOULOS; Nassera AOUALI; Ralf DUERRWALD; Jennifer HOWARD; Francisco POZO; Bartolome SASTRE-PALOU; Diana NONKOVIC; Mirjam J KNOL; Irina KISLAYA; Liem Binh Luong NGUYEN; Nathalie BOSSUYT; Thomas DEMUYSER; Ausra DZIUGYTE; Ivan MARTINEZ-BAZ; Corneliu POPESCU; Roisin DUFFY; Monika KULIESE; Lenka SOUČKOVÁ; Stella MICHELAKI; Marc SIMON; Janine REICHE; Maria Teresa OTERO-BARROS; Zvjezdana Lovric MAKARIC; Patricia C J L BRUIJNING-VERHAGEN; Veronica GOMEZ; Zineb LESIEUR; Cyril BARBEZANGE; Van Nedervelde ELS; Maria-Louise BORG; Jesus CASTILLA; Mihaela LAZAR; Joan DONNELL; Indre JONIKAITE; Regina DEMLOVÁ; Marina AMERALI; Gil WIRTZ; Kristin TOLKSDORF; Marta VALENCIANO; Sabrina BACCI a Esther KISSLING

Vydání

EUROSURVEILLANCE, STOCKHOLM, EUR CENTRE DIS PREVENTION & CONTROL, 2023, 1025-496X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30303 Infectious Diseases

Stát vydavatele

Švédsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 10.000

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/23:00133687

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Alpha; Delta; Europe; hospital; SARS-CoV-2; vaccine effectiveness

Štítky

14110214, 14110516, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 2. 2024 09:12, Mgr. Tereza Miškechová

Anotace

V originále

IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients >= 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine >= 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged >= 80 years. During the Delta period, among SARI patients >= 20 years with symptom onset >= 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) >= 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; >= 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.

Návaznosti

90249, velká výzkumná infrastruktura

Název: CZECRIN IV

Citovat

@article{2379808,
   author = {Angela, MC Rose and Nicolay, Nathalie and Martin, Virginia Sandonis and Mazagatos, Clara and Petrovic, Goranka and Niessen, F Annabel and Machado, Ausenda and Launay, Odile and Denayer, Sarah and Seyler, Lucie and Baruch, Joaquin and Burgui, Cristina and Loghin, Isabela I and Domegan, Lisa and Vaikutyte, Roberta and Husa, Petr and Panagiotakopoulos, George and Aouali, Nassera and Duerrwald, Ralf and Howard, Jennifer and Pozo, Francisco and SastreandPalou, Bartolome and Nonkovic, Diana and Knol, Mirjam J and Kislaya, Irina and Nguyen, Liem Binh Luong and Bossuyt, Nathalie and Demuyser, Thomas and Dziugyte, Ausra and MartinezandBaz, Ivan and Popescu, Corneliu and Duffy, Roisin and Kuliese, Monika and Součková, Lenka and Michelaki, Stella and Simon, Marc and Reiche, Janine and OteroandBarros, Maria Teresa and Makaric, Zvjezdana Lovric and BruijningandVerhagen, Patricia C J L and Gomez, Veronica and Lesieur, Zineb and Barbezange, Cyril and Els, Van Nedervelde and Borg, MariaandLouise and Castilla, Jesus and Lazar, Mihaela and Donnell, Joan and Jonikaite, Indre and Demlová, Regina and Amerali, Marina and Wirtz, Gil and Tolksdorf, Kristin and Valenciano, Marta and Bacci, Sabrina and Kissling, Esther},
   article_location = {STOCKHOLM},
   article_number = {47},
   doi = {https://doi.org/10.2807/1560-7917.ES.2023.28.47.2300186},
   keywords = {Alpha; Delta; Europe; hospital; SARS-CoV-2; vaccine effectiveness},
   language = {eng},
   issn = {1025-496X},
   journal = {EUROSURVEILLANCE},
   title = {Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021},
   url = {https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300186},
   volume = {28},
   year = {2023}
}

TY  - JOUR
ID  - 2379808
AU  - Angela, MC Rose - Nicolay, Nathalie - Martin, Virginia Sandonis - Mazagatos, Clara - Petrovic, Goranka - Niessen, F Annabel - Machado, Ausenda - Launay, Odile - Denayer, Sarah - Seyler, Lucie - Baruch, Joaquin - Burgui, Cristina - Loghin, Isabela I - Domegan, Lisa - Vaikutyte, Roberta - Husa, Petr - Panagiotakopoulos, George - Aouali, Nassera - Duerrwald, Ralf - Howard, Jennifer - Pozo, Francisco - Sastre-Palou, Bartolome - Nonkovic, Diana - Knol, Mirjam J - Kislaya, Irina - Nguyen, Liem Binh Luong - Bossuyt, Nathalie - Demuyser, Thomas - Dziugyte, Ausra - Martinez-Baz, Ivan - Popescu, Corneliu - Duffy, Roisin - Kuliese, Monika - Součková, Lenka - Michelaki, Stella - Simon, Marc - Reiche, Janine - Otero-Barros, Maria Teresa - Makaric, Zvjezdana Lovric - Bruijning-Verhagen, Patricia C J L - Gomez, Veronica - Lesieur, Zineb - Barbezange, Cyril - Els, Van Nedervelde - Borg, Maria-Louise - Castilla, Jesus - Lazar, Mihaela - Donnell, Joan - Jonikaite, Indre - Demlová, Regina - Amerali, Marina - Wirtz, Gil - Tolksdorf, Kristin - Valenciano, Marta - Bacci, Sabrina - Kissling, Esther
PY  - 2023
TI  - Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
JF  - EUROSURVEILLANCE
VL  - 28
IS  - 47
SP  - 1-16
EP  - 1-16
PB  - EUR CENTRE DIS PREVENTION & CONTROL
SN  - 1025496X
KW  - Alpha
KW  - Delta
KW  - Europe
KW  - hospital
KW  - SARS-CoV-2
KW  - vaccine effectiveness
UR  - https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300186
N2  - IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients >= 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine >= 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged >= 80 years. During the Delta period, among SARI patients >= 20 years with symptom onset >= 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) >= 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; >= 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.
ER  -

Přehled o publikaci